Literature DB >> 32350860

Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.

Philippine Eloy1,2, Caroline Solas3, Franck Touret4, France Mentré5, Denis Malvy6,7, Xavier de Lamballerie4, Jérémie Guedj5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32350860     DOI： 10.1002/cpt.1877

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  13 in total

1.  Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019.

Authors:  Pramod Kumar; Anand Kulkarni; Mithun Sharma; Padaki Nagaraja Rao; Duvvuru Nageshwar Reddy
Journal:  J Clin Transl Hepatol       Date:  2021-04-15

2.  Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".

Authors:  Yin-Xiao Du; Xiao-Ping Chen
Journal:  Clin Pharmacol Ther       Date:  2020-05-21       Impact factor: 6.875

3.  Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Authors:  Suzanne J F Kaptein; Sofie Jacobs; Lana Langendries; Laura Seldeslachts; Sebastiaan Ter Horst; Laurens Liesenborghs; Bart Hens; Valentijn Vergote; Elisabeth Heylen; Karine Barthelemy; Elke Maas; Carolien De Keyzer; Lindsey Bervoets; Jasper Rymenants; Tina Van Buyten; Xin Zhang; Rana Abdelnabi; Juanita Pang; Rachel Williams; Hendrik Jan Thibaut; Kai Dallmeier; Robbert Boudewijns; Jens Wouters; Patrick Augustijns; Nick Verougstraete; Christopher Cawthorne; Judith Breuer; Caroline Solas; Birgit Weynand; Pieter Annaert; Isabel Spriet; Greetje Vande Velde; Johan Neyts; Joana Rocha-Pereira; Leen Delang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-09       Impact factor: 11.205

Review 4.  The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies.

Authors:  Vaishali P Waman; Neeladri Sen; Mihaly Varadi; Antoine Daina; Shoshana J Wodak; Vincent Zoete; Sameer Velankar; Christine Orengo
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

5.  Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.

Authors:  Jiapeng Li; Shuhan Liu; Jian Shi; Xinwen Wang; Yanling Xue; Hao-Jie Zhu
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-01

Review 6.  An update of anti-viral treatment of COVID-19

Authors:  Serap Şimşek-Yavuz; Feride Ipek Komsuoğlu Çelikyurt
Journal:  Turk J Med Sci       Date:  2021-12-17       Impact factor: 0.973

7.  Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.

Authors:  Toshie Manabe; Dan Kambayashi; Hiroyasu Akatsu; Koichiro Kudo
Journal:  BMC Infect Dis       Date:  2021-05-27       Impact factor: 3.090

Review 8.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

Review 9.  The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).

Authors:  Neelu Batra; Cristabelle De Souza; Jyoti Batra; Alan G Raetz; Ai-Ming Yu
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

Review 10.  Favipiravir use for SARS CoV-2 infection.

Authors:  Alberto Boretti
Journal:  Pharmacol Rep       Date:  2020-10-27       Impact factor: 3.024
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.